ReviewClinics in chest medicine2013
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
Review in Clinics in chest medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.Nature communications · 2019Article
- FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.European journal of nuclear medicine and molecular imaging · 2018Article
- The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.Stem cell research & therapy · 2017Article
- Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Article
- Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.Scientific reports · 2016Article
- Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.Scientific reports · 2016Article
- Article
- Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype.EuPA open proteomics · 2016Article
- Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor.Case reports in pulmonology · 2016Article
- Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.Oncotarget · 2015Article
- Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.Immunology letters · 2015Article
- Changing pattern in malignant mesothelioma survival.Translational oncology · 2015Article
- Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.Molecular cancer · 2014Article
- Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.British journal of cancer · 2014Article
- Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.PloS one · 2014Article
- "Lower door open thoracotomy": a feasible approach for extra-pleural pneumonectomy.Journal of thoracic disease · 2013Article
- Diagnosis and management options in malignant pleural effusions.Lung India : official organ of Indian Chest SocietyReview
- Article
- Malignant Mesothelioma - Report of Two Cases with Different Presentations.Indian journal of occupational and environmental medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is evidence that improved treatments of malignant pleural mesothelioma are increasing the quality and quantity of life for patients with mesothelioma. Multimodality treatment programs that combine maximal surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of patients with mesothelioma. Lung-sparing surgery may allow improvements in pulmonary function after surgery-based multimodality therapy, and potential longer overall survival than that seen with extrapleural pneumonectomy. Experimental treatments provide hope for all patients with mesothelioma, and in the future may be combined with standard therapy in multimodality protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.